{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:13:02Z","timestamp":1762607582158,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.lrr.2024.100490","type":"journal-article","created":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T01:37:55Z","timestamp":1732412275000},"page":"100490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Treatment of Vietnamese patients diagnosed with myelodysplastic neoplasms: Practical experience in a developing country"],"prefix":"10.1016","volume":"23","author":[{"given":"Quang Hao","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5473-557X","authenticated-orcid":false,"given":"Minh Phuong","family":"Vu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ha Trang","family":"Kieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duc Binh","family":"Vu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ha Thanh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quoc Khanh","family":"Bach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lrr.2024.100490_bib0001","doi-asserted-by":"crossref","unstructured":"Marques F.K., Sabino A.P. Myelodysplastic neoplasms: an overview on diagnosis, risk-stratification, molecular pathogenesis, and treatment. Biomed. Pharmacother. 2022 Dec;156:113905. doi: 10.1016\/j.biopha.2022.113905. Epub 2022 Oct 25. PMID: 36306593.","DOI":"10.1016\/j.biopha.2022.113905"},{"issue":"7","key":"10.1016\/j.lrr.2024.100490_bib0002","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2024.100490_bib0003","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 2023 Aug;98(8):1307\u20131325. doi: 10.1002\/ajh.26984. Epub 2023 Jun 8. PMID: 37288607.","DOI":"10.1002\/ajh.26984"},{"key":"10.1016\/j.lrr.2024.100490_bib0004","doi-asserted-by":"crossref","unstructured":"Fenaux P., Haase D., Santini V., Sanz G.F., Platzbecker U., et al. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020\u2606. Ann. Oncol. 2021 Feb;32(2):142\u2013156. doi: 10.1016\/j.annonc.2020.11.002. Epub 2020 Nov 19. PMID: 33221366.","DOI":"10.1016\/j.annonc.2020.11.002"},{"key":"10.1016\/j.lrr.2024.100490_bib0005","doi-asserted-by":"crossref","unstructured":"Killick S.B., Ingram W., Culligan D., Enright H., Kell J., et al. British Society for Haematology guidelines for the management of adult myelodysplastic syndromes. Br. J. Haematol. 2021 Jul;194(2):267\u2013281. doi: 10.1111\/bjh.17612. Epub 2021 Jun 27. PMID: 34180045.","DOI":"10.1111\/bjh.17612"},{"key":"10.1016\/j.lrr.2024.100490_bib0006","doi-asserted-by":"crossref","unstructured":"Gasc\u00f3n P., Krendyukov A., Mathieson N., Aapro M. Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: a review of clinical data, clinical guidelines, and treatment protocols. Leuk. Res. 2019 Jun;81:35\u201342. doi: 10.1016\/j.leukres.2019.03.006. Epub 2019 Mar 27. PMID: 31005849.","DOI":"10.1016\/j.leukres.2019.03.006"},{"issue":"43","key":"10.1016\/j.lrr.2024.100490_bib0007","doi-asserted-by":"crossref","first-page":"73483","DOI":"10.18632\/oncotarget.19008","article-title":"Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions","volume":"8","author":"Valent","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.lrr.2024.100490_bib0008","doi-asserted-by":"crossref","unstructured":"Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006 Jul 15;108(2):419\u201325. doi: 10.1182\/blood-2005-10-4149. Epub 2006 Apr 11. PMID: 16609072.","DOI":"10.1182\/blood-2005-10-4149"},{"issue":"18","key":"10.1016\/j.lrr.2024.100490_bib0009","doi-asserted-by":"crossref","first-page":"7567","DOI":"10.1002\/cam4.2638","article-title":"Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: a propensity score-matched analysis","volume":"8","author":"Balleari","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.lrr.2024.100490_bib0010","doi-asserted-by":"crossref","unstructured":"Castelli R., Deliliers G.L., Colombo R., Moreo G., Gallipoli P., et al. Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function. Ann. Hematol. 2014 Sep;93(9):1523\u20139. doi: 10.1007\/s00277-014-2070-8. Epub 2014 Apr 8. PMID: 24711171.","DOI":"10.1007\/s00277-014-2070-8"},{"issue":"Supplement 1","key":"10.1016\/j.lrr.2024.100490_bib0011","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1182\/blood-2021-146461","article-title":"Lower-risk myelodysplastic syndromes: erythropoiesis-stimulating agent treatment approaches and outcomes in the United States","volume":"138","author":"Kristin","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2024.100490_bib0012","doi-asserted-by":"crossref","unstructured":"Xie M., Jiang Q., Xie Y. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants. Clin. Lymphoma Myeloma Leuk. 2015 Jan;15(1):22\u20138. doi: 10.1016\/j.clml.2014.04.010. Epub 2014 Jun 12. PMID: 25042977.","DOI":"10.1016\/j.clml.2014.04.010"},{"issue":"5","key":"10.1016\/j.lrr.2024.100490_bib0013","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.12669\/pjms.36.5.2289","article-title":"Clinical effect of decitabine in the treatment of myelodysplastic syndrome and influencing factors","volume":"36","author":"Liu","year":"2020","journal-title":"Pak. J. Med. Sci."},{"issue":"13","key":"10.1016\/j.lrr.2024.100490_bib0014","doi-asserted-by":"crossref","first-page":"13885","DOI":"10.1002\/cam4.5922","article-title":"Decitabine in patients with myelodysplastic syndromes: a multi-center, open-label, dose comparison trial","author":"Liu","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.lrr.2024.100490_bib0015","doi-asserted-by":"crossref","unstructured":"Feng X., Chen X., Nie S., Chang Y., Meng F., et al. Decitabine: an effective and safe treatment for myelodysplastic syndrome and acute myeloid leukemia. J. Cancer Res. Ther. 2019;15(7):1471\u20131476. doi: 10.4103\/0973-1482.204849. PMID: 31939424.","DOI":"10.4103\/0973-1482.204849"}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048924000803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048924000803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:08:47Z","timestamp":1762607327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048924000803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":15,"alternative-id":["S2213048924000803"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2024.100490","relation":{},"ISSN":["2213-0489"],"issn-type":[{"type":"print","value":"2213-0489"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Vietnamese patients diagnosed with myelodysplastic neoplasms: Practical experience in a developing country","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2024.100490","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100490"}}